Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Use-results survey of UPASITA IV Injection Syringe in hemodialysis patients
jRCT2041210113Active, not recruiting
- Sponsor
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of upacicalcet in secondary hyperparathyroidism (SHPT), sponsored by Sanwa Kagaku Kenkyusho Co., Ltd. Primary endpoints: Incidence of hypocalcaemia, Incidence of QT prolongation and 1 more. Started Feb 2022; status: active, not recruiting.
02
Drugs
upacicalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on jRCT2041210113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210113.